Introduction of Evercode Low Input Fixation Kits
Parse Biosciences has made a significant stride in the realm of single-cell sequencing with the launch of its Evercode™ Low Input Fixation kits. These innovative kits cater specifically to researchers who may have limited numbers of starting cells or nuclei, making single-cell sequencing much more accessible.
Addressing Challenges in Single Cell Sequencing
Traditionally, fixation technologies required researchers to begin their experiments with a substantial number of cells—typically around 50,000. This requirement posed a challenge for many in the scientific community, particularly those dealing with rare biological samples or minimal cell populations. With the launch of these new low input fixation kits, researchers can successfully initiate their studies with as few as 10,000 cells or nuclei, opening up new possibilities.
The Flexibility for Diverse Research Applications
These advanced kits provide researchers with enhanced flexibility, accommodating various experimental conditions. Now, customers can fix up to 96 samples at the same time using a plate format. This capability is especially crucial for applications that involve high-throughput drug screening and profiling patient samples from extensive cohorts.
The Vision Behind the Innovation
Charlie Roco, PhD, who is the chief technology officer and co-founder of Parse Biosciences, stated that the development of the Evercode Low Input Fixation kits stems directly from customer feedback. He emphasized that these kits represent a significant step towards improving access and flexibility for the research community when conducting single-cell studies.
Availability of Evercode Low Input Fixation Kits
The new fixation kits are readily available for shipment immediately. Moreover, the Parse team will present further details about these kits at the upcoming conference, including a chance to engage with the team in Booth #703 throughout the event.
About Parse Biosciences
Parse Biosciences is a pioneering life sciences company with a mission to bolster advancements in human health and scientific research. The organization specializes in empowering researchers by providing cutting-edge single-cell sequencing capabilities that enable monumental discoveries in fields such as cancer treatment, tissue repair, stem cell therapy, kidney and liver diseases, and brain development.
Founded by co-founders Alex Rosenberg and Charles Roco, the technology was born at the University of Washington. Parse has successfully raised over $100 million in funding and serves more than 2,000 clients worldwide. Its diverse product portfolio features solutions like Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a data analysis tool termed Trailmaker™.
Recently, Parse Biosciences expanded its operational footprint by moving into a new, state-of-the-art headquarters and laboratory located in Seattle’s South Lake Union district, further supporting its mission to advance research capabilities.
Frequently Asked Questions
What are Evercode Low Input Fixation kits?
Evercode Low Input Fixation kits are designed for researchers with limited numbers of starting cells, enabling them to effectively perform single-cell sequencing.
Who can benefit from these new kits?
These kits are ideal for scientists working with rare samples or small cell populations, as well as those conducting high-throughput drug screening.
How many samples can be processed at once?
Researchers can fix up to 96 samples simultaneously using the Evercode kits, which streamlines the research process significantly.
Where can I find more information about Parse Biosciences?
Further information can be found on Parse Biosciences' official website, where they detail their products and mission.
What is the significance of lower input requirements?
The lower input requirements empower more researchers to conduct experiments they previously couldn’t due to cell availability, potentially leading to new discoveries.
